Birch Triterpenes
drugOn this page
Also known as Betula alba bark powderBetula alba bark waterBetula alba subsp. pubescens barkBetula alba var. pubescens barkBetula pubescens barkBetulae cortexDowny birch barkEpisalvanFilsuvezShirakaba jyuhi ekisu
Summary
Birch Triterpenes (CHEMBL4650246) is an approved small molecule (ATC D03AX13); indicated across 6 conditions including injury and epidermolysis bullosa dystrophica.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D03AX13
- Indications: 6 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650246 |
| Name | Birch Triterpenes |
| Type | Small molecule |
| Max phase | 4 |
| ATC | D03AX13 |
Also known as: Betula alba bark powder, Betula alba bark water, Betula alba subsp. pubescens bark, Betula alba var. pubescens bark, Betula pubescens bark, Betulae cortex, Birch triterpenes, Downy birch bark, Episalvan, Filsuvez, Shirakaba jyuhi ekisu, BIRCH TRITERPENES
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| injury | 4 | MONDO:0021178 | EFO:0000546 |
| epidermolysis bullosa dystrophica | 4 | MONDO:0006543 | EFO:1000692 |
| junctional epidermolysis bullosa | 4 | MONDO:0017612 | MONDO:0017612 |
| epidermolysis bullosa | 1 | MONDO:0006541 | EFO:1000690 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06423573 | Not specified | RECRUITING | A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).